Acalabrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
British Journal of Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma
Br. J. Haematol 2022 Jul 21;[EPub Ahead of Print], P Strati, M Coleman, R Champion, S Ma, C Patti, MY Levy, IS Lossos, PR Geethakumari, S Lam, R Calvo, K Higgins, LE BuddeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.